Department of Biology, University of York, York, United Kingdom
Department of Animal and Plant Sciences, University of Sheffield, Sheffield, United Kingdom.
mBio. 2019 Sep 24;10(5):e01652-19. doi: 10.1128/mBio.01652-19.
Phage therapy is a promising alternative to chemotherapeutic antibiotics for the treatment of bacterial infections. However, despite recent clinical uses of combinations of phages to treat multidrug-resistant infections, a mechanistic understanding of how bacteria evolve resistance against multiple phages is lacking, limiting our ability to deploy phage combinations optimally. Here, we show, using and pairs of phages targeting shared or distinct surface receptors, that the timing and order of phage exposure determine the strength, cost, and mutational basis of resistance. Whereas sequential exposure allowed bacteria to acquire multiple resistance mutations effective against both phages, this evolutionary trajectory was prevented by simultaneous exposure, resulting in quantitatively weaker resistance. The order of phage exposure determined the fitness costs of sequential resistance, such that certain sequential orders imposed much higher fitness costs than the same phage pair in the reverse order. Together, these data suggest that phage combinations can be optimized to limit the strength of evolved resistances while maximizing their associated fitness costs to promote the long-term efficacy of phage therapy. Globally rising rates of antibiotic resistance have renewed interest in phage therapy where combinations of phages have been successfully used to treat multidrug-resistant infections. To optimize phage therapy, we first need to understand how bacteria evolve resistance against combinations of multiple phages. Here, we use simple laboratory experiments and genome sequencing to show that the timing and order of phage exposure determine the strength, cost, and mutational basis of resistance evolution in the opportunistic pathogen These findings suggest that phage combinations can be optimized to limit the emergence and persistence of resistance, thereby promoting the long-term usefulness of phage therapy.
噬菌体疗法是治疗细菌感染的一种有前途的替代化学治疗抗生素的方法。然而,尽管最近临床使用噬菌体组合来治疗多药耐药感染,但缺乏对细菌如何对多种噬菌体产生抗性的机制理解,限制了我们最佳部署噬菌体组合的能力。在这里,我们使用靶向共享或不同表面受体的噬菌体对和对,表明噬菌体暴露的时间和顺序决定了抗性的强度、成本和突变基础。虽然顺序暴露使细菌能够获得针对两种噬菌体都有效的多种抗性突变,但同时暴露阻止了这种进化轨迹,导致抗性的强度降低。噬菌体暴露的顺序决定了顺序抗性的适应成本,因此某些顺序顺序比相反顺序的相同噬菌体对施加更高的适应成本。总之,这些数据表明,可以优化噬菌体组合以限制进化抗性的强度,同时最大化其相关的适应成本,以促进噬菌体治疗的长期疗效。抗生素耐药性的全球上升重新引发了人们对噬菌体治疗的兴趣,噬菌体组合已成功用于治疗多药耐药感染。为了优化噬菌体治疗,我们首先需要了解细菌如何对多种噬菌体的组合产生抗性。在这里,我们使用简单的实验室实验和基因组测序表明,噬菌体暴露的时间和顺序决定了机会性病原体中抗性进化的强度、成本和突变基础。这些发现表明,可以优化噬菌体组合以限制抗性的出现和持续,从而促进噬菌体治疗的长期有效性。